

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/011367 A1

(51) International Patent Classification⁷:
5/10, C12N 15/82, 5/04, C07K 14/765

A01H 5/00,

(74) Agents: **CHRISTENBURY, Daniel, T. et al.**; Piper Rud-
nick LLP, 3400 Two Logan Square, 18th and Arch Streets,
Philadelphia, PA 19103 (US).

(21) International Application Number:

PCT/US2003/021158

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 3 July 2003 (03.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (*for all designated States except US*): UNI-
VERSITY OF CENTRAL FLORIDA [US/US]; Office
of Technology Transfer, 4000 Central Florida Boulevard,
Orlando, FL 32816-0150 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventor; and



(75) Inventor/Applicant (*for US only*): **DANIEL, Henry**
[US/US]; 1440 Pelican Bay Trail, Winter Park, FL 32792
(US).

Published:

— with international search report

[Continued on next page]

(54) Title: A CHLOROPLAST TRANSGENIC APPROACH TO EXPRESS AND PURIFY HUMAN SERUM ALBUMIN, A PRO-
TEIN HIGHLY SUSCEPTIBLE TO PROTEOLYTIC DEGRADATION



(57) Abstract: Production of human serum albumin (HSA) in prokaryotic systems has not been successful to date because HSA is highly susceptible to proteolytic degradation. Production in plants has not yielded enough protein to be cost-effective. The instant invention overcomes this by producing HSA in plant plastids at high levels.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.